X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Natco Pharma with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs ADCOCK INGRAM (S. Africa) - Comparison Results

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 NATCO PHARMA   ADCOCK INGRAM
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
ADCOCK INGRAM
Jun-14
NATCO PHARMA/
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs877403-   
Low Rs424291-   
Sales per share (Unadj.) Rs223.4119.9-  
Earnings per share (Unadj.) Rs31.1-30.2-  
Cash flow per share (Unadj.) Rs40.3-25.0-  
Dividends per share (Unadj.) Rs5.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs219.594.1-  
Shares outstanding (eoy) m33.07168.78-   
Bonus/Rights/Conversions PA--  
Price / Sales ratio x2.92.9 100.6%   
Avg P/E ratio x20.9-11.5 -182.3%  
P/CF ratio (eoy) x16.1-13.9 -116.5%  
Price / Book Value ratio x3.03.7 80.4%  
Dividend payout %16.10-   
Avg Mkt Cap Rs m21,50458,557 36.7%   
No. of employees `000NA4.3 0.0%   
Total wages/salary Rs m1,1283,675 30.7%   
Avg. sales/employee Rs ThNM4,714.3-  
Avg. wages/employee Rs ThNM856.1-  
Avg. net profit/employee Rs ThNM-1,187.9-  
INCOME DATA
Net Sales Rs m7,38920,238 36.5%  
Other income Rs m167142 117.9%   
Total revenues Rs m7,55620,380 37.1%   
Gross profit Rs m1,793-3,507 -51.1%  
Depreciation Rs m304873 34.8%   
Interest Rs m366548 66.8%   
Profit before tax Rs m1,290-4,787 -26.9%   
Minority Interest Rs m46-13 -347.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m309299 103.2%   
Profit after tax Rs m1,027-5,100 -20.1%  
Gross profit margin %24.3-17.3 -140.1%  
Effective tax rate %23.9-6.2 -383.0%   
Net profit margin %13.9-25.2 -55.2%  
BALANCE SHEET DATA
Current assets Rs m3,68114,823 24.8%   
Current liabilities Rs m3,1238,340 37.4%   
Net working cap to sales %7.632.0 23.6%  
Current ratio x1.21.8 66.3%  
Inventory Days Days89111 80.7%  
Debtors Days Days59124 47.3%  
Net fixed assets Rs m7,6858,640 88.9%   
Share capital Rs m33194 351.9%   
"Free" reserves Rs m6,6700-   
Net worth Rs m7,25915,885 45.7%   
Long term debt Rs m9555,582 17.1%   
Total assets Rs m11,95730,008 39.8%  
Interest coverage x4.5-7.7 -58.5%   
Debt to equity ratio x0.10.4 37.4%  
Sales to assets ratio x0.60.7 91.6%   
Return on assets %11.7-15.2 -76.8%  
Return on equity %14.2-32.1 -44.1%  
Return on capital %20.7-19.8 -104.6%  
Exports to sales %39.40-   
Imports to sales %5.70-   
Net fx Rs m2,7430-   
CASH FLOW
From Operations Rs m1,4401,727 83.4%  
From Investments Rs m-1,089-530 205.3%  
From Financial Activity Rs m-3535,066 -7.0%  
Net Cashflow Rs m-16,263 -0.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 5.56 Rs / ZAR

Compare NATCO PHARMA With: MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare NATCO PHARMA With: SANOFI INDIA  DISHMAN PHARMA  ALEMBIC LTD  FULFORD INDIA  PIRAMAL ENTERPRISES  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views On News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Feb 23, 2018 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 8-QTR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS